treatment of hrd-negative ovarian cancer
Published 4 years ago • 780 plays • Length 4:42Download video MP4
Download video MP3
Similar videos
-
8:41
impact of hrd status on frontline treatment of ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
6:28
ovarian cancer: what is the role of hrd testing?
-
6:08
treating ovarian cancer based on hrd status
-
6:21
parp inhibition in brca1/2 or hrd- ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
7:34
parp inhibition’s role in recurrent ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
3:51
treating homologous recombination proficient ovarian cancer
-
1:25
dr. borst on homologous recombination deficiency in patients with ovarian cancer
-
1:13:10
the state of ovarian cancer: exploring the landscape of systemic therapy
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
0:40
dr. willmott on fda approval of maintenance olaparib in ovarian cancer
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
1:25
dr. emens on the combination of checkpoint inhibitors and parp inhibitors in ovarian cancer
-
5:38
management of parp inhibitor aes in ovarian cancer